BD Reports Second Quarter Fiscal 2026 Financial Results

Original from: Becton, Dickinson and Company

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

"We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Execution was broad-based, with more than 90% of the business delivering mid‑single‑digit growth, strong performance from our growth platforms and ongoing margin momentum from BD Excellence. Based on our first‑half performance and improved visibility into the balance of the year, we are raising our full‑year adjusted EPS guidance and reaffirming our revenue growth expectations. We remain focused on disciplined execution of our New BD strategy, including advancing our commercial and innovation initiatives across key growth platforms, expanding margins, and delivering on our capital allocation framework, all to drive sustainable long‑term shareholder value."

Recent Business Highlights

- Medical Essentials:

 · Announced the commercial launch of the BD® CentroVena One™ Insertion System, the first all-in-one central venous catheter (CVC) insertion device on the market designed to simplify central line placement and enhance patient safety in acute settings.

- Connected Care:

 · Announced a strategic partnership with Wellstar Health System to advance patient care and safety with medication management powered by AI, building a more connected approach from the pharmacy to the bedside by integrating the BD® Pyxis™ Pro and BD® Alaris™ Platforms to give clinicians clearer insight, greater accuracy and simple automation.

 · Launched the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe, leveraging advanced automation and AI‑driven insights to improve medication management efficiency and safety across pharmacy settings.

 · Launched the HemoSphere Stream™ Module, expanding access to continuous, noninvasive blood pressure monitoring with real‑time arterial waveform data across compatible bedside monitors and care settings.

 · Announced a partnership with Sinteco to expand advanced robotics for end‑to‑end connected medication management, streamlining pharmacy operations and supporting higher‑quality care.

 · Earned three 2026 Best in KLAS Awards with BD Pyxis™ MedStation™ ES recognized for Automated Dispensing Cabinets and the BD Alaris™ Infusion System for Traditional and EHR-Integrated Smart Pumps.

- Interventional:

 · Received CE Marking for the Revello™ Vascular Covered Stent, advancing BD's peripheral vascular portfolio with a next-generation endovascular solution for iliac artery treatment.

 · Received CE Marking for the Liverty™ TIPS Stent Graft, advancing portal hypertension care with a next‑generation interventional solution for patients with advanced liver disease.

 · Received FDA 510(k) clearance for Surgiphor™ 1000mL, the first and only 1000 mL antimicrobial wound irrigation system designed for powered lavage, enabling standardized, OR‑ready irrigation.

- BD named a Top 100 Global Innovator by LexisNexis, reflecting the strength of BD's innovation engine and contributions to sustainable growth, margin expansion and competitive advantage.

Basis of Presentation— Continuing Operations

On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.

Full Year Fiscal 2026 Guidance

The company updates its full year fiscal 2026 guidance as follows:

BD's guidance for full year fiscal 2026 reflects numerous assumptions that could affect its business, based on the information management has reviewed as of this date. Management will discuss its guidance and several of its assumptions on its second fiscal quarter earnings call.

The company's expected adjusted diluted EPS for fiscal 2026 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our revenue growth for our 2026 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying revenue performance for our 2026 fiscal year in relation to our underlying 2025 fiscal year performance.

Source: BD Reports Second Quarter Fiscal 2026 Financial Results